INTEGRAL BIOPHARMA LTD

Company Registration Number:
12456898 (England and Wales)

Unaudited abridged accounts for the year ended 31 July 2023

Period of accounts

Start date: 01 August 2022

End date: 31 July 2023

INTEGRAL BIOPHARMA LTD

Contents of the Financial Statements

for the Period Ended 31 July 2023

Balance sheet
Notes

INTEGRAL BIOPHARMA LTD

Balance sheet

As at 31 July 2023


Notes

2023

2022


£

£
Fixed assets
Tangible assets: 3 56,624 75,024
Total fixed assets: 56,624 75,024
Current assets
Debtors:   12,754 19,946
Cash at bank and in hand: 266,262 332,414
Total current assets: 279,016 352,360
Creditors: amounts falling due within one year:   (73,220) (75,135)
Net current assets (liabilities): 205,796 277,225
Total assets less current liabilities: 262,420 352,249
Total net assets (liabilities): 262,420 352,249
Capital and reserves
Called up share capital: 100 100
Profit and loss account: 262,320 352,149
Shareholders funds: 262,420 352,249

The notes form part of these financial statements

INTEGRAL BIOPHARMA LTD

Balance sheet statements

For the year ending 31 July 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 30 July 2024
and signed on behalf of the board by:

Name: R Mahmood
Status: Director

The notes form part of these financial statements

INTEGRAL BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

The turnover shown in the profit and loss account represents amounts invoiced during the period, exclusive of value added tax and trade discounts.

Tangible fixed assets and depreciation policy

Fixed assetsAll fixed assets are initially recorded at cost.DepreciationDepreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value based on prices prevailing at the date of acquisition of each asset evenly over its expected useful life, as follows;

Other accounting policies

Foreign currenciesMonetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.Operating Leases & Other leasesLeases are classified as finance leases whenever they transfer substantially all the risks and rewards of ownership to the company. The assets are included in property, plant and equipment or capitalised software and the capital elements of the leasing commitments are shown as obligations under finance leases. The assets are depreciated on a basis consistent with similar owned assets or the lease term if shorter. The interest element of the lease rental is included in the income statement.All other leases are classified as operating leases and the rentals payable are expensed on a straight line basis over the lease term.Pension costsContributions to the defined contribution company pension scheme are charged to the profit and loss account as incurred.TaxationThe taxation charge in the profit and loss account is based on the profit for the year as adjusted for disallowable and non-taxable items using current rates and takes into account tax deferred because of timing differences between the treatment of certain items for taxation and accounting purposes.

INTEGRAL BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

2. Employees

2023 2022
Average number of employees during the period 4 4

INTEGRAL BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

3. Tangible Assets

Total
Cost £
At 01 August 2022 95,212
Additions 499
At 31 July 2023 95,711
Depreciation
At 01 August 2022 20,188
Charge for year 18,899
At 31 July 2023 39,087
Net book value
At 31 July 2023 56,624
At 31 July 2022 75,024

INTEGRAL BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

4. Financial commitments

At 31 July 2023, the company had annual commitments under non-cancellable operating leases.